Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 1/2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Colorectal Neoplasms 36Pancreatic Neoplasms 26Rectal Neoplasms 15Esophageal Neoplasms 13Colonic Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 8Gastrointestinal Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma Of Esophagus 7Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Melanoma 3Liver Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Kidney Neoplasms 2Gastrointestinal Diseases 2Endometrial Neoplasms 2Carcinoma 2

Interventions

pembrolizumab 30Nivolumab 15Paclitaxel 13Cyclophosphamide 12Carboplatin 12sacituzumab govitecan 8Cisplatin 8Capecitabine 7130-nm albumin-bound paclitaxel 7Gemcitabine 6fludarabine 5durvalumab 5avelumab 5atezolizumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Biopsy 5camrelizumab 4Specimen Handling 4Interleukin-2 4Injections 4Immune Checkpoint Inhibitors 4Docetaxel 4toripalimab 3talazoparib 3Leucovorin 3Everolimus 3Clinical Trials, Phase II as Topic 3Bevacizumab 3yeast-CEA vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Triple Negative Breast Neoplasms × Fluorouracil × Clear all
NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Breast

Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

ImmunityBio, Inc.

Phase 1/2 Terminated
9 enrolled 18 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡